Collapsible/expandable prosthetic heart valves with native calcified leaflet retention features

Information

  • Patent Grant
  • 9615921
  • Patent Number
    9,615,921
  • Date Filed
    Thursday, September 10, 2015
    9 years ago
  • Date Issued
    Tuesday, April 11, 2017
    7 years ago
Abstract
A prosthetic heart valve includes an annular frame that is adapted for (1) delivery into a patient's native heart valve annulus in a circumferentially collapsed condition, and (2) circumferential re-expansion when in the annulus, the frame, in an expanded condition. The frame having a longitudinal axis, an inflow end and an outflow end, a first portion of the frame adjacent the inflow end inclining radially outwardly in a direction toward the inflow end, and a second portion of the frame between the first portion and the outflow end bulging radially outwardly, the second portion of the frame being positioned between a first axial distance from the inflow end and a second axial distance from the inflow end. The frame also includes a plurality of commissure members. The heart valve further includes a flexible leaflet structure disposed in the frame.
Description
BACKGROUND OF THE INVENTION

This invention relates to collapsible/expandable prosthetic heart valves (especially prosthetic aortic valves) for use with non-resected calcified native valves. The prosthetic heart valve design incorporates features that hold open the native calcified leaflets away from the new valve.


BRIEF SUMMARY OF THE INVENTION

In accordance with certain possible aspects of the invention, a prosthetic heart valve may utilize expansion of fork-like fingers to push calcified native leaflets out of the way. This eliminates interference with the newly deployed prosthetic valve and maximizes hemodynamic performance. It also enhances prosthetic valve frame anchoring in the patient as a result of the fingers engaging the calcified leaflets.


A prosthetic heart valve in accordance with the invention may be circumferentially collapsible and re-expandable, and may include an annular frame structure and a flexible leaflet structure disposed in the frame structure. The frame structure is preferably adapted for delivery into a patient's native heart valve annulus in a circumferentially collapsed condition. The frame structure is preferably further adapted for circumferential re-expansion when in the above-mentioned annulus. The frame structure preferably includes a leaflet restraining structure for pushing radially outwardly on a patient's native heart valve leaflet (or leaflets) when the frame structure is re-expanded. The leaflet restraining structure is preferably cantilevered from an annulus portion of the frame structure. (The annulus portion is the portion of the frame structure that re-expands in the native valve annulus.) More particularly, the leaflet restraining structure is preferably cantilevered from the annulus portion to a free end of the leaflet restraining structure that is downstream from the annulus portion in the direction of blood flow through the prosthetic valve when the prosthetic valve is in use in the patient.


The above-mentioned leaflet restraining structure may be resiliently biased to incline radially outwardly from the annulus portion as one proceeds along the restraining structure from the annulus portion toward the free end of the restraining structure.


The leaflet restraining structure may include a plurality of fingers that are spaced from one another in a direction that is circumferential around the annulus portion. Each of these fingers may be cantilevered from the annulus portion and may extend from the annulus portion in the direction of blood flow through the implanted prosthetic valve.


Each of the above-mentioned fingers may have a free end that is remote from the annulus portion. All of the fingers may extend to approximately the same distance downstream from the annulus portion in the direction of blood flow. Alternatively, a first of the fingers may extend a greater distance downstream from the annulus portion in the direction of blood flow than a second of the fingers.


The annulus portion may include two (or more) circumferentially spaced commissure regions. In such a case, and in the case of the alternative mentioned in the immediately preceding paragraph, the fingers may also be circumferentially spaced from one another between two of the commissure regions, and the above-mentioned first finger may be circumferentially closer to one of the above-mentioned two commissure regions than the above-mentioned second finger is to either of those two commissure regions.


In a case in which the leaflet restraining structure includes a plurality of fingers, the leaflet restraining structure may further include a linking structure between two circumferentially adjacent ones of the fingers. This linking structure may be downstream from the annulus portion in the direction of blood flow through the implanted prosthetic valve.


The immediately above-mentioned linking structure may be collapsible and re-expandable in a direction that is circumferential around the annulus portion.


The location of the above-mentioned linking structure may be at the ends of the linked fingers that are remote from the annulus portion.


The annulus portion may include a plurality of circumferentially spaced commissure regions, and the leaflet restraining structure may be circumferentially spaced between two circumferentially adjacent ones of those commissure regions. Especially in such a case, the leaflet restraining structure may be one of a plurality of similar leaflet restraining structures. Each of these leaflet restraining structures may be circumferentially spaced between a respective one of a plurality of pairs of circumferentially adjacent ones of the commissure regions.


The prosthetic heart valve may be an aortic valve, which may further comprise a further frame structure that includes an annular aortic portion and a plurality of struts or links between the aortic portion and the annulus portion. The aortic portion may be adapted for delivery into a patient's aorta in a circumferentially collapsed condition. The aortic portion may be further adapted to circumferentially re-expand when in the aorta. The aortic portion is preferably downstream from the free end of the leaflet restraining structure in the direction of blood flow. The above-mentioned struts or links are preferably circumferentially spaced from the leaflet restraining structure.


In cases like those mentioned in the immediately preceding paragraph, the annulus portion may include a plurality of circumferentially spaced commissure regions. The above-mentioned struts or links may then connect to the annulus portion adjacent the commissure regions. For example, the leaflet restraining structure may be circumferentially spaced between first and second circumferentially adjacent ones of the links, and the first and second links may be respectively connected to the annulus portion adjacent respective first and second circumferentially adjacent ones of the commissure regions.


Further features of the invention, its nature and various advantages, will be more apparent from the accompanying drawings and the following detailed description.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1a is a simplified isometric or perspective view of an illustrative embodiment of a prosthetic heart valve in accordance with the invention.



FIG. 1b shows the FIG. 1a structure from another angle.



FIG. 1c shows the FIG. 1b structure from yet another angle.



FIG. 1d shows the FIG. 1c structure from still another angle.



FIG. 2a is a view similar to FIG. 1a for another illustrative embodiment of a prosthetic heart valve in accordance with the invention.



FIG. 2b shows the FIG. 2a structure from another angle.



FIG. 2c is similar to FIG. 2b, but FIG. 2c shows only some of the structure that is shown in FIG. 2b.



FIG. 2d shows the FIG. 2c structure from another angle.



FIG. 3a is a simplified view of an illustrative embodiment of a prosthetic heart valve component in accordance with the invention. FIG. 3a shows the depicted component as though cut along a vertical axis and then laid out flat.



FIG. 3b is similar to FIG. 3a for another illustrative embodiment of the invention.



FIG. 3c is similar to FIG. 3b for yet another illustrative embodiment of the invention.



FIG. 3d is similar to FIG. 3c for still another illustrative embodiment of the invention.





DETAILED DESCRIPTION

A collapsible and re-expandable prosthetic aortic valve that can self-anchor around the native commissures in the valsalva sinus is shown in Alkhatib PCT patent application No. PCT/US08/09950, filed Aug. 21, 2008, which is hereby incorporated by reference herein in its entirety. The illustrations that form part of the present disclosure are embodiments of valves like those shown in the above-mentioned reference, with the addition of leaflet retention or restraining features in accordance with this invention. It will be understood that the particular structures shown and described herein are only illustrative, and that the invention can be applied to many other prosthetic valve constructions. Some of these possible variations will be mentioned later in this specification.



FIGS. 1a-d are several views of an illustrative embodiment of the invention, including fork-like fingers 10 for pushing a patient's native leaflet tissue (which may be calcified) out of the way of the leaflet structure 20 of prosthetic heart valve 30. The upper free ends of fingers 10 are cantilevered from annular stent structure 40 of the valve. When the valve is implanted in a patient, stent structure 40 resides in or near the patient's native valve annulus. Hence this portion 40 of the frame structure of valve 30 may sometimes be referred to as the annulus portion of the frame structure. Valve 30 is configured for use as an aortic valve replacement. In such use, an annular aortic portion 50 of the valve resides in the patient's aorta downstream (in the direction of blood flow through the implanted valve) from the patient's native valve annulus. Portions 40 and 50 are connected to one another by a plurality of links or struts 60 that pass through the patient's native valsalva sinus and that bulge out into the outwardly bulging lobes of the valsalva sinus. Other details of the construction of valve 30 will more apparent from the above-mentioned Alkhatib reference.


Note that all of the valves shown herein may be elastically collapsible in the annular or circumferential direction to a reduced annular or circumferential size that is suitable for delivery into a patient in a less invasive way (e.g., through tube-like delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like). When the valve reaches the intended site for implantation, the valve may elastically re-expand to normal operating size (e.g., the size shown in FIGS. 1a-d). In all cases herein, the valve frame structure like 10/40/50/60 may be made of a highly elastic metal such as nitinol, while leaflet structure 20 may be made of a synthetic material such as polymer, a natural material such as tissue, or another suitable flexible material. In addition to the structural elements shown herein, valves in accordance with this invention may also include other elements such as other layers of tissue and/or fabric (e.g., an outer fabric cover).



FIGS. 2a-d are several views of another illustrative embodiment of the invention. Reference numbers are repeated from FIGS. 1a-d for features in FIGS. 2a-d that are similar to features in FIGS. 1a-d. FIGS. 2c and d omit depiction of the actual leaflet structure 20 to better reveal certain other features. The principal difference from FIGS. 1a-d is the inclusion in FIGS. 2a-d of collapsible/expandable interconnections 12 between the upper (cantilevered) ends of certain ones of fork-like fingers 10.



FIGS. 3a-d show several further alternative embodiments of the metal frame structure 10/40/50/60/etc. of valves in accordance with the invention. Again, reference numbers are repeated from earlier FIGS. for generally similar components. FIGS. 3a-d show each metal frame structure as though it has been cut along a longitudinal (vertical) axis and then laid out flat. In addition, FIGS. 3a-d show each metal structure in the approximate condition (especially from left to right as viewed in these FIGS.) that it has when annularly collapsed for delivery into a patient in reduced annular or circumferential size. Thus the serpentine or cellular structures (e.g., 40, 50, 12) that extend in the annular direction around the valve are somewhat collapsed or compressed in the left-right direction as viewed in FIGS. 3a-d. Annular portions 40 and 50 shown in FIGS. 3a-d are of a closed-cell design. This is an alternative embodiment to the undulating strut design shown in the earlier FIGS. (Again, it is emphasized that the structures shown in FIGS. 3a-d are not actually flat at any time during their use. They are always closed, annular structures. The flat depictions shown in FIGS. 3a-d are only employed for convenience herein.)


In FIG. 3a the upper ends of cantilevered fork-like fingers 10 are free (e.g., as in FIGS. 1a-d), but these fingers differ in length. In particular, fingers 10 are longer near (in the circumferential direction) each of the three circumferentially spaced commissure posts 42 of the valve, and shorter where farther (in the circumferential direction) from the commissure posts. Another way to state this is by saying that the fingers 10 that are circumferentially closer to commissure posts 42 extend farther in the distal or downstream direction than the fingers 10 that are circumferentially farther from the commissure posts. FIG. 3b shows fingers 10 all of the same length and with their upper ends free.



FIG. 3c shows an embodiment like FIG. 3a, but with the upper ends of the fingers 10 of different lengths linked by serpentine structures 12. Note that each serpentine structure 12 links only the fingers 10 in a set of such fingers that are located between two circumferentially adjacent ones of commissure posts 42. Thus the fingers 10 in such a set and the serpentine structure 12 linking those fingers collectively comprise a leaflet restraining structure that is cantilevered upwardly from annulus portion 40 of the prosthetic valve frame. This structure as a whole (i.e., the set of fingers 10 and the link 12) has a free end (i.e., its upper end, which in this case is defined by link 12).



FIG. 3d shows an embodiment like FIG. 3b, but with the upper ends of equal-length fingers 10 linked by serpentine structures 12. Once again, in FIG. 3d, each set of fingers 10 (between two circumferentially adjacent commissure posts) and the associated link 12 collectively constitute a leaflet restraining structure that is cantilevered up from annulus portion 40 to a free end (i.e., link 12). In embodiments without links 12, the fingers 10 themselves constitute the leaflet restraining structure of this invention.


Recapitulating and extending the above, the following are some of the important aspects of the invention.


Features 10 (possibly with links 12) are incorporated onto a collapsible valve frame and are designed specifically to hold the native calcified leaflet back (e.g., radially outwardly) and away from the replacement valve.


Features 10 (possibly with links 12) are preferably not tall enough such that they would obstruct the coronary artery ostia.


The cantilevered leaflet retention feature typically includes several elongated, curved, fork-like fingers 10 that can be free-standing or interconnected (e.g., as shown at 12) at the distal (downstream) end.


The fingers 10 are connected to the main stent frame at their proximal (upstream) end.


The fork-like fingers 10 may be curved radially outward, away from the replacement valve.


The fork-like fingers 10 (possibly with links 12) have adequate stiffness in the radial direction to hold the calcified native valve in an open (radially outward) position.


The fork-like fingers 10 (possibly with links 12) can be scalloped (e.g., FIG. 3a or 3c) or straight (e.g., FIG. 3b or 3d) at their distal end.


The fork-like fingers 10 (possibly with links 12) enhance anchoring of the prosthetic valve as a result of engaging the calcified leaflets.


While curved (radially) outward fork-like members 10 will do a good job keeping calcified leaflets out of the way, alternate designs can also be used, ranging from straight up fingers 10 to straight fingers inclined at an angle so that they are radially farther out at their free ends than where joined to annulus portion 40. Preferably, the prosthetic valve frame's geometry is designed to oppose the native leaflet once implanted and is capable of holding open, pushing outwards, engaging, and displacing the native leaflets in desired patterns to clear coronaries, and anchoring in the native leaflets. Many suitable geometries are capable of achieving these goals. The geometries can vary significantly and only some of the possible geometries are described herein.


Although the presently preferred stent structures (like 10/40/50/60) are self-expanding (i.e., elastically deformed), the present invention is equally applicable to balloon-expandable (i.e., plastically deformed) stents or a combination of self-expanding and balloon expandable (e.g., where arms like 10 are resiliently self-expanding, but the rest of the cage like 40/50/60 may be balloon-expanded). The balloon-expandable stents, which can be made of stainless steel, can be used with specifically designed balloons that have, for example, a bulbous midsection. The balloon-expendable stents can also be enlarged in two or more steps. A straight conventional balloon can be used first to anchor one or more stent structures of the valves. A second spherical balloon can then be used to specifically expand the other structure or structures such as fingers 10.


The structures like fingers 10 of this invention can also be designed to provide the following benefits. These structures preferably move the native calcified leaflets radially outwardly away from the new valve structure to avoid potential abrasion of the new valve tissue 20 against the calcified, diseased tissue. Use of this invention can provide more space for a bigger prosthetic valve and better hemodynamics. The structures like 10/12 of this invention can deform the diseased leaflets in such a way as to avoid potential coronary blockage (i.e. occlusion of the ostium of a coronary artery). The structures like 10/12 can be designed to also help with stability and anchoring of the prosthetic valve in the patient. Prior known collapsible prosthetic valves may include cages that are intended to push diseased leaflets out of the way. But these previously known structures do not attempt to control or preferentially displace the diseased leaflets in a specific configuration to provide the benefits described above for the present invention.


The attachment point of fingers 10 to the stent is described as being preferably at or near the proximal end of the prosthetic valve frame structure using the proximal end of the fingers. In another embodiment of the invention, the fingers can extend down from the distal end of stent (outflow side). Other combinations of attachment are also possible (e.g., stent inflow side and members 60 or stent outflow side and members 60).


The foregoing features can be incorporated on minimally invasive surgically implanted valves where resection of the native calcified leaflets has not been performed or is not possible.


An advantage of providing leaflet restraining structures 10/12 as structures that are cantilevered from other structure of the valve frame is that this facilitates giving the leaflet restraining structures various properties that can be relatively independent of the properties of other parts of the frame. For example, the extent to which leaflet restraining structures 10/12 incline or extend radially outwardly can be made to depend solely (or at least largely) on the design of those structures per se, and can be independent of the shape, location, etc., of other adjacent frame components such as links 60, commissure posts 42, aortic portion 50, etc. Similarly, those other portions of the valve can be designed to have properties that are independent of the properties of leaflet restraining structures 10/12. Examples of properties that can thus be designed independently for structures 10/12, on the one hand, and other portions of the frame, on the other hand, include (1) collapsed location (i.e., location during delivery), (2) re-expanded location (i.e., location when deployed and implanted in the patient), (3) size, (4) shape, (5) stiffness, (6) strength, (7) resilience, etc.


It will be understood that the foregoing is only illustrative of the principles of the invention, and that various modifications can be made by those skilled in the art without departing from the scope and spirit of the invention. For example, the number of leaflet restraining structures that are provided can be more or less than the number shown herein.

Claims
  • 1. A prosthetic heart valve comprising: an annular frame that is adapted for (1) delivery into a patient's native heart valve annulus in a circumferentially collapsed condition, and (2) circumferential re-expansion when in the annulus, the frame, in an expanded condition, having a longitudinal axis, an inflow end and an outflow end, a first portion of the frame adjacent the inflow end inclining radially outwardly in a direction toward the inflow end, and a second portion of the frame between the first portion and the outflow end bulging radially outwardly, the second portion of the frame being positioned between a first axial distance from the inflow end and a second axial distance from the inflow end, the frame further having a first radius at an intersection of the first portion and the second portion, the second portion having a plurality of radii greater than the first radius, the frame also including a plurality of commissure members positioned between the first axial distance from the inflow end and the second axial distance from the inflow end; anda flexible leaflet structure disposed in the frame.
  • 2. The prosthetic valve as claimed in claim 1, wherein the flexible leaflet structure includes three leaflets.
  • 3. The prosthetic valve as claimed in claim 2, wherein the leaflets are formed from a biological tissue.
  • 4. The prosthetic valve as claimed in claim 1, wherein the flexible leaflet structure further includes an outer fabric cover.
  • 5. The prosthetic valve as claimed in claim 1, wherein the flexible leaflet structure is at least partially disposed within the first portion of the frame.
  • 6. The prosthetic valve as claimed in claim 1, wherein the flexible leaflet structure is at least partially disposed within the second portion of the frame.
  • 7. The prosthetic valve as claimed in claim 1, wherein the flexible leaflet structure is coupled to the frame at the plurality of commissure members.
  • 8. The prosthetic valve as claimed in claim 1, wherein the frame includes a plurality of struts forming cells.
  • 9. The prosthetic valve as claimed in claim 1, wherein the frame is self-expanding.
  • 10. A prosthetic valve, comprising: a frame having an expanded configuration and a collapsed configuration, the frame in the expanded configuration having a longitudinal axis, an inflow end and an outflow end, the frame having a first portion adjacent the inflow end inclining radially outward in a direction toward the inflow end, a second portion adjacent the outflow end, and a middle portion between the first and second portions, an intersection of the first portion with the middle portion defining a first radius from the longitudinal axis, and an intersection of the second portion with the middle portion defining a second radius from the longitudinal axis, all of a plurality of points on a surface of the middle portion having a radius from the longitudinal axis that is greater than the first radius and the second radius, the frame further including a plurality of commissure members at least partially disposed adjacent the middle portion; anda valve assembly supported by the frame and coupled to the plurality of commissure members.
  • 11. The prosthetic valve as claimed in claim 10, wherein the first portion inclines radially outwardly in a direction toward the inflow end.
  • 12. The prosthetic valve as claimed in claim 10, wherein the valve assembly further includes an outer fabric cover.
  • 13. The prosthetic valve as claimed in claim 10, wherein the valve assembly includes three leaflets.
  • 14. The prosthetic valve as claimed in claim 13, wherein the leaflets are formed from a biological tissue.
  • 15. The prosthetic valve as claimed in claim 10, wherein the frame includes a plurality of struts forming cells.
  • 16. The prosthetic valve as claimed in claim 10, wherein the frame is self-expanding.
  • 17. The prosthetic valve as claimed in claim 10, wherein the frame is balloon-expandable.
  • 18. The prosthetic valve as claimed in claim 10, wherein the valve assembly is at least partially disposed within the middle portion.
  • 19. The prosthetic valve as claimed in claim 10, wherein the valve assembly is at least partially disposed within the first portion.
Parent Case Info

This application is a continuation application of U.S. application Ser. No. 14/824,209, filed Aug. 12, 2015, which is a continuation application of U.S. application Ser. No. 14/280,868, filed May 19, 2014 which is a continuation application of U.S. application Ser. No. 12/733,763, filed Mar. 18, 2010, which is a national phase entry under 35 U.S.C. §371 of International Application No. PCT/US2008/11181, filed Sep. 26, 2008, published in English, which claims the benefit of U.S. Provisional Patent Application No. 60/995,845, filed Sep. 28, 2007, the disclosures of all of which are hereby incorporated herein by reference.

US Referenced Citations (221)
Number Name Date Kind
3657744 Ersek Apr 1972 A
4192020 Davis et al. Mar 1980 A
4275469 Gabbay Jun 1981 A
4340091 Skelton et al. Jul 1982 A
4423730 Gabbay Jan 1984 A
4491986 Gabbay Jan 1985 A
4731074 Rousseau et al. Mar 1988 A
4759758 Gabbay Jul 1988 A
4878906 Lindemann et al. Nov 1989 A
4922905 Strecker May 1990 A
4994077 Dobben Feb 1991 A
5411552 Andersen et al. May 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5843167 Dwyer et al. Dec 1998 A
5855601 Bessler et al. Jan 1999 A
5924424 Stevens et al. Jul 1999 A
5935163 Gabbay Aug 1999 A
5961549 Nguyen et al. Oct 1999 A
5968068 Dehdashtian et al. Oct 1999 A
6077297 Robinson et al. Jun 2000 A
6083257 Taylor et al. Jul 2000 A
6090140 Gabbay Jul 2000 A
6168614 Andersen et al. Jan 2001 B1
6214036 Letendre et al. Apr 2001 B1
6264691 Gabbay Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6306141 Jervis Oct 2001 B1
6312465 Griffin et al. Nov 2001 B1
6358277 Duran Mar 2002 B1
6368348 Gabbay Apr 2002 B1
6419695 Gabbay Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6454799 Schreck Sep 2002 B1
6468660 Ogle et al. Oct 2002 B2
6488702 Besselink Dec 2002 B1
6517576 Gabbay Feb 2003 B2
6533810 Hankh et al. Mar 2003 B2
6582464 Gabbay Jun 2003 B2
6610088 Gabbay Aug 2003 B1
6623518 Thompson et al. Sep 2003 B2
6685625 Gabbay Feb 2004 B2
6719789 Cox Apr 2004 B2
6726715 Sutherland Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6767362 Schreck Jul 2004 B2
6783556 Gabbay Aug 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6814746 Thompson et al. Nov 2004 B2
6830584 Seguin Dec 2004 B1
6830585 Artof et al. Dec 2004 B1
6869444 Gabbay Mar 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6893460 Spenser et al. May 2005 B2
6908481 Cribier Jun 2005 B2
6916338 Speziali Jul 2005 B2
7018406 Seguin Mar 2006 B2
7025780 Gabbay Apr 2006 B2
7041132 Quijano et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7101396 Artof et al. Sep 2006 B2
7137184 Schreck Nov 2006 B2
7160322 Gabbay Jan 2007 B2
7247167 Gabbay Jul 2007 B2
7267686 DiMatteo et al. Sep 2007 B2
7311730 Gabbay Dec 2007 B2
7329278 Seguin et al. Feb 2008 B2
7331993 White Feb 2008 B2
7374573 Gabbay May 2008 B2
7381218 Schreck Jun 2008 B2
7452371 Pavcnik et al. Nov 2008 B2
7510572 Gabbay Mar 2009 B2
7524331 Birdsall Apr 2009 B2
RE40816 Taylor et al. Jun 2009 E
7585321 Cribier Sep 2009 B2
7682390 Seguin Mar 2010 B2
7708775 Rowe May 2010 B2
7731742 Schlick et al. Jun 2010 B2
7799072 Greenberg Sep 2010 B2
7803185 Gabbay Sep 2010 B2
7846203 Cribier Dec 2010 B2
7846204 Letac et al. Dec 2010 B2
7871436 Ryan et al. Jan 2011 B2
7914569 Nguyen et al. Mar 2011 B2
D648854 Braido Nov 2011 S
D652926 Braido Jan 2012 S
D652927 Braido et al. Jan 2012 S
D653341 Braido et al. Jan 2012 S
D653342 Braido et al. Jan 2012 S
D653343 Ness et al. Jan 2012 S
D654169 Braido Feb 2012 S
D654170 Braido et al. Feb 2012 S
D660432 Braido May 2012 S
D660433 Braido et al. May 2012 S
D660967 Braido et al. May 2012 S
8444689 Zhang May 2013 B2
D684692 Braido Jun 2013 S
8454686 Alkhatib Jun 2013 B2
8465540 Straubinger et al. Jun 2013 B2
8597349 Alkhatib Dec 2013 B2
8728154 Alkhatib May 2014 B2
8784481 Alkhatib et al. Jul 2014 B2
8808366 Braido et al. Aug 2014 B2
8882831 Alkhatib Nov 2014 B2
8961595 Alkhatib Feb 2015 B2
9364321 Alkhatib Jun 2016 B2
20020036220 Gabbay Mar 2002 A1
20030023303 Palmaz et al. Jan 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030055496 Cai et al. Mar 2003 A1
20030130726 Thorpe et al. Jul 2003 A1
20030153974 Spenser et al. Aug 2003 A1
20030153975 Byrd et al. Aug 2003 A1
20040039436 Spenser et al. Feb 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040088046 Speziali May 2004 A1
20040093060 Seguin et al. May 2004 A1
20040093075 Kuehne May 2004 A1
20040186563 Lobbi Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20050096726 Sequin et al. May 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050177227 Heim et al. Aug 2005 A1
20050192665 Spenser et al. Sep 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050209689 Speziali Sep 2005 A1
20050256566 Gabbay Nov 2005 A1
20060008497 Gabbay Jan 2006 A1
20060074484 Huber Apr 2006 A1
20060106415 Gabbay May 2006 A1
20060122692 Gilad et al. Jun 2006 A1
20060142848 Gabbay Jun 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060167468 Gabbay Jul 2006 A1
20060173532 Flagle et al. Aug 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060190074 Hill et al. Aug 2006 A1
20060206202 Bonhoeffer et al. Sep 2006 A1
20060241744 Beith Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060259120 Vongphakdy et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060265056 Nguyen et al. Nov 2006 A1
20060276813 Greenberg Dec 2006 A1
20070010876 Salahieh et al. Jan 2007 A1
20070027534 Bergheim et al. Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070055358 Krolik et al. Mar 2007 A1
20070067029 Gabbay Mar 2007 A1
20070073391 Bourang et al. Mar 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070093890 Eliasen et al. Apr 2007 A1
20070100435 Case et al. May 2007 A1
20070112422 Dehdashtian May 2007 A1
20070118210 Pinchuk May 2007 A1
20070162100 Gabbay Jul 2007 A1
20070168013 Douglas Jul 2007 A1
20070203575 Forster et al. Aug 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070239271 Nguyen Oct 2007 A1
20070244545 Birdsall et al. Oct 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070282436 Pinchuk Dec 2007 A1
20070288087 Fearnot et al. Dec 2007 A1
20080021552 Gabbay Jan 2008 A1
20080039934 Styrc Feb 2008 A1
20080071368 Tuval et al. Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080082164 Friedman Apr 2008 A1
20080097595 Gabbay Apr 2008 A1
20080114452 Gabbay May 2008 A1
20080125853 Bailey et al. May 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080147179 Cai et al. Jun 2008 A1
20080147182 Righini et al. Jun 2008 A1
20080147183 Styrc Jun 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080228263 Ryan Sep 2008 A1
20080228264 Li et al. Sep 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080243246 Ryan et al. Oct 2008 A1
20080255662 Stacchino et al. Oct 2008 A1
20080262602 Wilk et al. Oct 2008 A1
20080269879 Sathe et al. Oct 2008 A1
20090054975 del Nido et al. Feb 2009 A1
20090082858 Nugent Mar 2009 A1
20090112309 Jaramillo et al. Apr 2009 A1
20090138079 Tuval et al. May 2009 A1
20100004740 Seguin et al. Jan 2010 A1
20100036484 Hariton et al. Feb 2010 A1
20100036485 Seguin Feb 2010 A1
20100049306 House et al. Feb 2010 A1
20100087907 Lattouf Apr 2010 A1
20100114307 Agnew et al. May 2010 A1
20100131054 Tuval et al. May 2010 A1
20100131055 Case et al. May 2010 A1
20100168778 Braido Jul 2010 A1
20100168839 Braido et al. Jul 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100204781 Alkhatib Aug 2010 A1
20100204785 Alkhatib Aug 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100249911 Alkhatib Sep 2010 A1
20100249923 Alkhatib et al. Sep 2010 A1
20100286768 Alkhatib Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20110029072 Gabbay Feb 2011 A1
20110082539 Suri Apr 2011 A1
20110224678 Gabbay Sep 2011 A1
20120078347 Braido et al. Mar 2012 A1
20130245753 Alkhatib Sep 2013 A1
20140236289 Alkhatib Aug 2014 A1
20140296966 Braido et al. Oct 2014 A1
20150032206 Alkhatib Jan 2015 A1
Foreign Referenced Citations (43)
Number Date Country
19857887 Jul 2000 DE
10121210 Nov 2002 DE
202008009610 Dec 2008 DE
0331345 Sep 1989 EP
0850607 Jul 1998 EP
1000590 May 2000 EP
1129744 Sep 2001 EP
1157673 Nov 2001 EP
1360942 Nov 2003 EP
1584306 Oct 2005 EP
1598031 Nov 2005 EP
1926455 Jun 2008 EP
2847800 Jun 2004 FR
2850008 Jul 2004 FR
9117720 Nov 1991 WO
9716133 May 1997 WO
9832412 Jul 1998 WO
9913801 Mar 1999 WO
0128459 Apr 2001 WO
0149213 Jul 2001 WO
0154625 Aug 2001 WO
0156500 Aug 2001 WO
0176510 Oct 2001 WO
0236048 May 2002 WO
0247575 Jun 2002 WO
03047468 Jun 2003 WO
2004047619 Jun 2004 WO
2006073626 Jul 2006 WO
2007013999 Feb 2007 WO
2007053243 May 2007 WO
2007071436 Jun 2007 WO
2008070797 Jun 2008 WO
2009029199 Mar 2009 WO
2009042196 Apr 2009 WO
2009045332 Apr 2009 WO
2009045334 Apr 2009 WO
2010008548 Jan 2010 WO
2010008549 Jan 2010 WO
2010051025 May 2010 WO
2010087975 Aug 2010 WO
2010096176 Aug 2010 WO
2010098857 Sep 2010 WO
2013075215 May 2013 WO
Non-Patent Literature Citations (22)
Entry
PCT International Search Report for Application No. PCT/US2008/011153 dated Jan. 26, 2009.
U.S. Appl. No. 29/375,232.
U.S. Appl. No. 29/375,235.
U.S. Appl. No. 29/375,238.
U.S. Appl. No. 29/375,239.
U.S. Appl. No. 29/375,245.
U.S. Appl. No. 29/375,251.
U.S. Appl. No. 29/375,252.
U.S. Appl. No. 29/375,253.
U.S. Appl. No. 29/375,254.
U.S. Appl. No. 29/375,257.
U.S. Appl. No. 29/375,258.
U.S. Appl. No. 29/375,260.
International Search Report for Application No. PCT/US2008/011181 dated Feb. 18, 2009.
Design U.S. Appl. No. 29/375,243, filed Sep. 20, 2010.
Ruiz, Carlos, “Overview of PRE-CE Mark Transcatheter Aortic Valve Technologies”, Euro PCR, May 25, 2010.
Quaden, René et al., “Percutaneous aortic valve replacement: resection before implantation,” 836-840, European J. of Cardio-thoracic Surgery 27 (2005).
Knudsen, L.L. et al., Catheter-implanted prosthetic heart valves, The International Journal of Artificial Organs, vol. 16, No. 5 1993, pp. 253-262.
Transluminal Aortic Valve Placement, Moazami, Nader, et al., ASAIO Journal, 1996; 42:M381-M385.
Andersen, Henning Rud, Transluminal Catheter Implanted Prosthetic Heart Valves, International Journal of Angiology 7:102-106 (1998).
Andersen, H. R. et al, Transluminal implantation of artificial heart valves, European Heart Journal (1992) 13, 704-708.
Zegdi, Rachid, MD, PhD et al., “Is It Reasonable to Treat All Calcified Stenotic Aortic Valves With a Valved Stent?” 579-584, J. of the American College of Cardiology, vol. 51, No. 5, Feb. 5, 2008.
Related Publications (1)
Number Date Country
20150374490 A1 Dec 2015 US
Provisional Applications (1)
Number Date Country
60995845 Sep 2007 US
Continuations (3)
Number Date Country
Parent 14824209 Aug 2015 US
Child 14850018 US
Parent 14280868 May 2014 US
Child 14824209 US
Parent 12733763 US
Child 14280868 US